Quality of Life and Laryngopharyngeal Reflux.


Journal

Digestive diseases and sciences
ISSN: 1573-2568
Titre abrégé: Dig Dis Sci
Pays: United States
ID NLM: 7902782

Informations de publication

Date de publication:
09 2023
Historique:
received: 21 05 2023
accepted: 26 06 2023
medline: 24 8 2023
pubmed: 6 7 2023
entrez: 6 7 2023
Statut: ppublish

Résumé

Laryngopharyngeal reflux (LPR) is characterized by the reflux of gastric contents into the pharynx or larynx and often presents with symptoms including but not limited to cough, throat clearing, sore throat, globus, and dysphonia. Unlike gastroesophageal reflux disease (GERD), LPR is a relatively understudied syndrome, and knowledge regarding the diagnostic and treatment strategies, as well as the psychosocial impact continues to evolve. No singular test or procedure currently exists as a gold standard for LPR diagnosis. While laryngoscopy or pH monitoring may be positive, this does not exclude the contribution of non-gastroenterological processes. Prior research into psychosocial impact demonstrates a significant increase in symptom burden when comparing patients with laryngeal symptoms to controls and those with isolated GERD symptoms. However, these data are limited by the absence of physiologic data to correlate with the reported symptoms and survey responses. This knowledge gap highlights the need for further research to investigate the relationship between symptom burden and pathologic acid reflux on quality of life (QOL), anxiety, and depression. Ultimately, future studies to directly analyze these variables will help to guide treatment strategies and improve QOL in these patients.

Identifiants

pubmed: 37410247
doi: 10.1007/s10620-023-08027-8
pii: 10.1007/s10620-023-08027-8
doi:

Types de publication

Journal Article Review Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

3527-3533

Subventions

Organisme : NIDDK NIH HHS
ID : T32 DK007202
Pays : United States
Organisme : NIDDK NIH HHS
ID : K23 DK125266
Pays : United States
Organisme : NIDDK NIH HHS
ID : R03 DK135513
Pays : United States

Informations de copyright

© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Références

Krause AJ, Walsh EH, Weissbrod PA, Taft TH, Yadlapati R. An update on current treatment strategies for laryngopharyngeal reflux symptoms. Ann N Y Acad Sci. 2022;1510:5–17. https://doi.org/10.1111/nyas.14728 .
doi: 10.1111/nyas.14728 pubmed: 34921412
Brown HJ, Kuhar HN, Plitt MA, Husain I, Batra PS, Tajudeen BA. The Impact of Laryngopharyngeal Reflux on Patient-reported Measures of Chronic Rhinosinusitis. Ann Otol Rhinol Laryngol. 2020;129:886–893. https://doi.org/10.1177/0003489420921424 .
doi: 10.1177/0003489420921424 pubmed: 32390460
Katz PO, Dunbar KB, Schnoll-Sussman FH, Greer KB, Yadlapati R, Spechler SJ. ACG Clinical Guideline for the Diagnosis and Management of Gastroesophageal Reflux Disease. Am J Gastroenterol. 2022;117:27–56. https://doi.org/10.14309/ajg.0000000000001538 .
doi: 10.14309/ajg.0000000000001538 pubmed: 34807007 pmcid: 8754510
Lenderking WR, Hillson E, Crawley JA, Moore D, Berzon R, Pashos CL. The clinical characteristics and impact of laryngopharyngeal reflux disease on health-related quality of life. Value Health 2003;6:560–565. https://doi.org/10.1046/j.1524-4733.2003.65243.x .
doi: 10.1046/j.1524-4733.2003.65243.x pubmed: 14627062
Krause AJ, Greytak M, Burger ZC, Taft T, Yadlapati R. Hypervigilance and Anxiety are Elevated Among Patients With Laryngeal Symptoms With and Without Laryngopharyngeal Reflux. Clin Gastroenterol Hepatol. Oct 26 2022;doi: https://doi.org/10.1016/j.cgh.2022.10.017
Yadlapati R, Gyawali CP, Pandolfino JE. AGA Clinical Practice Update on the Personalized Approach to the Evaluation and Management of GERD: Expert Review. Clin Gastroenterol Hepatol. 2022;20:984-994.e1. https://doi.org/10.1016/j.cgh.2022.01.025 .
doi: 10.1016/j.cgh.2022.01.025 pubmed: 35123084 pmcid: 9838103
Brazier JE, Harper R, Jones NM et al. Validating the SF-36 health survey questionnaire: new outcome measure for primary care. Bmj. 1992;305:160–164. https://doi.org/10.1136/bmj.305.6846.160 .
doi: 10.1136/bmj.305.6846.160 pubmed: 1285753 pmcid: 1883187
Lins L, Carvalho FM. SF-36 total score as a single measure of health-related quality of life: Scoping review. SAGE Open Med. 2016;4:2050312116671725. https://doi.org/10.1177/2050312116671725 .
doi: 10.1177/2050312116671725 pubmed: 27757230 pmcid: 5052926
Shah CH, Brown JD. Reliability and Validity of the Short-Form 12 Item Version 2 (SF-12v2) Health-Related Quality of Life Survey and Disutilities Associated with Relevant Conditions in the U.S. Older Adult Population. J Clin Med. Feb 29 2020;9. doi: https://doi.org/10.3390/jcm9030661
Soh SE, Morello R, Ayton D, et al (2021) Measurement properties of the 12-item Short Form Health Survey version 2 in Australians with lung cancer: a Rasch analysis. Health Qual Life Outcomes 19:157. doi: https://doi.org/10.1186/s12955-021-01794-w
Djukanovic I, Carlsson J, Årestedt K. Is the Hospital Anxiety and Depression Scale (HADS) a valid measure in a general population 65–80 years old? A psychometric evaluation study. Health Qual Life Outcomes. Oct 4 2017;15:193. doi: https://doi.org/10.1186/s12955-017-0759-9
Bjelland I, Dahl AA, Haug TT, Neckelmann D. The validity of the Hospital Anxiety and Depression Scale. An updated literature review. J Psychosom Res. Feb 2002;52:69–77. doi: https://doi.org/10.1016/s0022-3999(01)00296-3
Hopkins C, Gillett S, Slack R, Lund VJ, Browne JP. Psychometric validity of the 22-item Sinonasal Outcome Test. Clin Otolaryngol. 2009;34:447–454. https://doi.org/10.1111/j.1749-4486.2009.01995.x .
doi: 10.1111/j.1749-4486.2009.01995.x pubmed: 19793277
Toma S, Hopkins C. Stratification of SNOT-22 scores into mild, moderate or severe and relationship with other subjective instruments. Rhinology. 2016;54:129–133. https://doi.org/10.4193/Rhino15.072 .
doi: 10.4193/Rhino15.072 pubmed: 27017484
Belafsky PC, Postma GN, Koufman JA. Validity and reliability of the reflux symptom index (RSI). J Voice. 2002;16:274–277. https://doi.org/10.1016/s0892-1997(02)00097-8 .
doi: 10.1016/s0892-1997(02)00097-8 pubmed: 12150380
Abraham ZS, Kahinga AA. Utility of reflux finding score and reflux symptom index in diagnosis of laryngopharyngeal reflux disease. https://doi.org/10.1002/lio2.799 . Laryngoscope Investigative Otolaryngology. 2022/06/01 2022;7:785–789. doi: https://doi.org/10.1002/lio2.799
Murry T, Rosen CA. Outcome measurements and quality of life in voice disorders. Otolaryngol Clin North Am. 2000;33:905–916. https://doi.org/10.1016/s0030-6665(05)70251-6 .
doi: 10.1016/s0030-6665(05)70251-6 pubmed: 10918668
Kim SI, Kwon OE, Na SY, Lee YC, Park JM, Eun YG. Association between 24-hour combined multichannel intraluminal impedance-pH monitoring and symptoms or quality of life in patients with laryngopharyngeal reflux. Clin Otolaryngol. 2017;42:584–591. https://doi.org/10.1111/coa.12817 .
doi: 10.1111/coa.12817
Carrau RL, Khidr A, Gold KF et al. Validation of a quality-of-life instrument for laryngopharyngeal reflux. Arch Otolaryngol Head Neck Surg. 2005;131:315–320. https://doi.org/10.1001/archotol.131.4.315 .
doi: 10.1001/archotol.131.4.315 pubmed: 15837899
McCaffrey N, Kaambwa B, Currow DC, Ratcliffe J. Health-related quality of life measured using the EQ-5D-5L: South Australian population norms. Health Qual Life Outcomes. Sep 20 2016;14:133. doi: https://doi.org/10.1186/s12955-016-0537-0
Taft TH, Triggs JR, Carlson DA et al. Validation of the oesophageal hypervigilance and anxiety scale for chronic oesophageal disease. Aliment Pharmacol Ther. 2018;47:1270–1277. https://doi.org/10.1111/apt.14605 .
doi: 10.1111/apt.14605 pubmed: 29528128 pmcid: 5897170
Carrau RL, Khidr A, Crawley JA, Hillson EM, Davis JK, Pashos CL. The impact of laryngopharyngeal reflux on patient-reported quality of life. Laryngoscope. 2004;114:670–674. https://doi.org/10.1097/00005537-200404000-00014 .
doi: 10.1097/00005537-200404000-00014 pubmed: 15064622
Cheung TK, Lam PK, Wei WI et al. Quality of life in patients with laryngopharyngeal reflux. Digestion. 2009;79:52–57. https://doi.org/10.1159/000205267 .
doi: 10.1159/000205267 pubmed: 19252403
Lechien JR, Finck C, Huet K, et al. Impact of age on laryngopharyngeal reflux disease presentation: a multi-center prospective study. European Archives of Oto-Rhino-Laryngology. 2017/10/01 2017;274:3687–3696. doi: https://doi.org/10.1007/s00405-017-4671-z
Siupsinskiene N, Adamonis K, Toohill RJ. Quality of life in laryngopharyngeal reflux patients. Laryngoscope. 2007;117:480–484. https://doi.org/10.1097/MLG.0b013e31802d83cf .
doi: 10.1097/MLG.0b013e31802d83cf pubmed: 17334308
Gong EJ, Choi KD, Jung HK et al. Quality of life, patient satisfaction, and disease burden in patients with gastroesophageal reflux disease with or without laryngopharyngeal reflux symptoms. J Gastroenterol Hepatol. 2017;32:1336–1340. https://doi.org/10.1111/jgh.13716 .
doi: 10.1111/jgh.13716 pubmed: 28052406
Koufman JA. Low-acid diet for recalcitrant laryngopharyngeal reflux: therapeutic benefits and their implications. Ann Otol Rhinol Laryngol. 2011;120:281–287. https://doi.org/10.1177/000348941112000501 .
doi: 10.1177/000348941112000501 pubmed: 21675582
Campagnolo AM, Priston J, Thoen RH, Medeiros T, Assunção AR. Laryngopharyngeal reflux: diagnosis, treatment, and latest research. Int Arch Otorhinolaryngol. 2014;18:184–191. https://doi.org/10.1055/s-0033-1352504 .
doi: 10.1055/s-0033-1352504 pubmed: 25992088

Auteurs

Kelli Liu (K)

Department of Medicine, University of California San Diego, La Jolla, CA, USA.

Amanda Krause (A)

Department of Medicine, Division of Gastroenterology & Hepatology, University of California San Diego, 9500 Gilman Drive MC0956, La Jolla, CA, 92093, USA.

Rena Yadlapati (R)

Department of Medicine, Division of Gastroenterology & Hepatology, University of California San Diego, 9500 Gilman Drive MC0956, La Jolla, CA, 92093, USA. ryadlapati@health.ucsd.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH